浏览全部资源
扫码关注微信
Foxg1抑制肝癌细胞血管形成及其机制
Foxg1 inhibits angiogenesis in hepatocellular carcinoma
in vitro - 第三军医大学学报 2018年40卷第6期 页码：494-499
- 作者机构：
1.400010 重庆，重庆医科大学附属第二医院肿瘤科
2.400038 重庆，陆军军医大学(第三军医大学)第一附属医院生物治疗中心
- 作者简介：
[ 张献全，E-mail：xqzhng@hotmali.com ZHANG Xianquan, E-mail: xqzhng@hotmali.com
[ 钱程，E-mail:cqian3184@163.com QIAN Cheng, E-mail: cqian3184@163.com
- 基金信息：国家自然科学基金重点项目(81330048)
DOI：10.16016/j.1000-5404.201711040
中图分类号： R394.2; R730.23; R735.7收稿：2017-11-07，
修回：2017-12-05，
纸质出版：2018-03-30
- 稿件说明：
移动端阅览
章凡, 张献全, 钱程. Foxg1抑制肝癌细胞血管形成及其机制[J]. 第三军医大学学报, 2018,40(6):494-499.
Fan ZHANG, Xianquan ZHANG, Cheng QIAN. Foxg1 inhibits angiogenesis in hepatocellular carcinoma
in vitro [J]. Journal of Third Military Medical University, 2018, 40(6): 494-499.章凡, 张献全, 钱程. Foxg1抑制肝癌细胞血管形成及其机制[J]. 第三军医大学学报, 2018,40(6):494-499. DOI： 10.16016/j.1000-5404.201711040.
Fan ZHANG, Xianquan ZHANG, Cheng QIAN. Foxg1 inhibits angiogenesis in hepatocellular carcinoma
in vitro [J]. Journal of Third Military Medical University, 2018, 40(6): 494-499. DOI： 10.16016/j.1000-5404.201711040.
摘要
目的
2
通过干扰和过表达肝癌细胞中的Foxg1，探讨Foxg1对人脐静脉血管内皮细胞(human umbilical vein endothelial cells，HUVEC)血管生成能力的影响及其机制。
方法
2
实验分为Hep3B干扰组、Hep3B对照组、Huh7过表达组和Huh7对照组，提取各组细胞条件培养基(conditional medium，CM)；通过Transwell实验、管腔形成实验观察各组CM对HUVEC的迁移及管腔形成的影响；采用实时荧光定量PCR(RT-PCR)及Western blot检测血管内皮生长因子A(vascular endothelial growth factor A，VEGFA)在各组肝癌细胞中的mRNA及蛋白水平，酶联免疫吸附实验(ELISA)检测各组CM内VEGFA浓度；采用Western blot检测4组肝癌细胞AKT1、p-AKT1的蛋白水平。
结果
2
Hep3B干扰组较Hep3B对照组CM的作用下，HUVEC细胞的迁移数显著增多(
P
＜0.01)，Huh7过表达组较Huh7对照组CM的作用下，HUVEC细胞迁移数显著减少(
P
＜0.01)；Hep3B干扰组CM的作用下，HUVEC细胞管腔形成数多于Hep3B对照组CM(
P
＜0.01)，而Huh7过表达组CM的作用下，HUVEC细胞管腔形成数少于Huh7对照组CM(
P
＜0.01)；Hep3B干扰组较Hep3B对照组VEGFA水平上调，Huh7过表达组较Huh7对照组VEGFA水平下调；Hep3B干扰组CM较Hep3B对照组CM的VEGFA水平上调，Huh7过表达组CM较Huh7对照组CM的VEGFA水平下调(
P
＜0.01)；Hep3B干扰组较Hep3B对照组AKT1磷酸化水平升高，Huh7过表达组较Huh7对照组AKT1磷酸化水平降低。
结论
2
Foxg1抑制肝癌血管生成的过程可能是通过抑制PI3K/Akt通路的激活下调VEGFA的表达来实现的。
Abstract
Objective
2
To investigate the effect of forkhead box G1 (Foxg1) on the angiogenesis of human umbilical vein endothelial cells(HUVECs)by interfering and overexpressing Foxg1 in hepatoma cells
and explore its underlying mechanisms.
Methods
2
The hepatocellular carcinoma cell lines Hep3B and Huh7 were used in this experiment
and after corresponding transfection
the cells were divided into 4 groups
that is
Hep3B shFoxg1 group (Foxg1 silence)
Hep3B control group
Huh7 expFog1 group (Foxg1 overexpression) and Huh7 control group. After the HUVECs were treated with the conditioned mediums (CM) from the above 4 groups of cells
transwell assay and tube formation assay were used to observe the effect of CM on migration and tube formation of HUVECs. The mRNA and protein levels of vascular endothelial growth factor A (VEGFA) in each group were measured by real-time fluorescence quantitative PCR (RT-PCR) and Western blotting. The concentration of VEGFA in the CM was detected by enzyme-linked immunosorbent assay (ELISA). Finally
Western blotting was used to detect the protein levels of AKT1 and p-AKT1 in the 4 groups of cells.
Results
2
The number of cell migration was significantly larger in the HUVECs exposure to CM from the Hep3B shFoxg1 group than that from Hep3B control group (
P
＜0.01)
while the number was smaller in the HUVECs treated with Huh7 expFoxg1 group CM than with Huh7 control group CM(
P
＜0.01). The CM from the Hep3B shFoxg1 group promoted tube formation in HUVECs when compared with the CM from the Hep3B control group (
P
＜0.01)
and the CM of the Huh7 expFoxg1 group induced less formation than the CM from the Huh7 control group(
P
＜0.01). RT-PCR and Western blotting showed that the VEGFA level was higher in the Hep3B shFoxg1 group than the Hep3B control group (
P
＜0.01)
and that in the Huh7 expFoxg1 group was down-regulated than the Huh7 control group (
P
＜0.01).Western blot analysis showed that the Hep3B shFoxg1 group had enhanced phosphorylation of AKT1 than the Hep3B control group
while the level was opposite in the Huh7 expFoxg1 group than the Huh7 control group.
Conclusion
2
Foxg1 inhibits the angiogenesis of hepatocellular carcinoma
which may be through suppressing the PI3K/AKT pathway and down-regulating the expression of VEGFA.
关键词
Keywords
references
ZHU A X, DUDA D G, SAHANI D V, et al . HCC and angiogenesis: possible targets and future directions[J ] . Nat Rev Clin Oncol, 2011, 8(5): 292-301. DOI: 10.1038/nrclinonc.2011.30.
BISHAYEE A, DARVESH A S. Angiogenesis in hepatocellular carcinoma:a potential target for chemoprevention and therapy[J]. Curr Cancer Drug Targets, 2012, 12(9): 1095-1118.
王芳芳, 罗蓉. FOXG1基因及FOXG1相关疾病的研究进展[J].华西医学, 2017, 32(5): 772-776.
WANG F F, LUO R.Research progress of FOXG1 gene and FOXG1-related diseases[J]. West China Med J, 2017, 32(5): 772-776.
GOLSON M L, KAESTNER K H. Fox transcription factors: from development to disease[J]. Development, 2016, 143(24): 4558-4570. DOI: 10.1242/dev.112672.
CHAN D W, LIU V W S, TO R M Y, et al . Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer[J ] . Br J Cancer, 2009, 101(8): 1433-1443. DOI: 10.1038/sj.bjc.6605316.
ZENG F, XUE M, XIAO T, et al . MiR-200b promotes the cell proliferation and metastasis of cervical cancer by inhibiting FOXG1[J ] . Biomed Pharmacother, 2016, 79: 294-301. DOI: 10.1016/j.biopha.2016.02.033.
ADESINA A M, NGUYENY, GUANARATNE P, et al . FOXG1, is overexpressed in hepatoblastoma[J ] . Hum Pathol, 2007, 38(3): 400-409.DOI: 10.1016/j.humpath.2006.09.003.
邵志伟. FOXG1的表达与人恶性神经胶质瘤的相关性研究[D]. 青岛: 青岛大学, 2015.
SHAO Z W. Related research between FOXG1 expression and human malignant glioma[D]. Qingdao: Qingdao University, 2015.
HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013.
DAI L, CUI X, ZHANG X, et al . SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin[J ] . Nat Commun, 2016, 7: 11996-12010. DOI: 10.1038/ncomms11996.
KHEMLINA G, IKEDA S, KURZROCK R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies[J]. Mol Cancer, 2017, 16(1): 149-158. DOI: 10.1186/s12943-017-0712-x.
BUPATHI M, KASEB A, MERIC-BERNSTAM F, et al . Hepatocellular carcinoma: where there is unmet need[J ] . Mol Oncol, 2015, 9(8): 1501-1509. DOI: 10.1016/j.molonc.2015.06.005.
STARZL T E. The long reach of liver transplantation[J]. Nat Med, 2012, 18(10): 1489-1492. DOI: 10.1038/nm.2927.
LE M, NELSON R, LEE W, et al . An appraisal of radiofrequency ablation and surgical resection for hepatocellular carcinoma: results from the surveillance, epidemiology, and end results registry[J ] . Am Surg, 2012, 78(10): 1091-1095.
JIANG B H, LIU L Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis[J]. Adv Cancer Res, 2009, 102(1): 19-65. DOI: 10.1016/S0065-230X(09)02002-8.
CARMELIET P, JAIN R K. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature, 2011, 473(7347): 298-307. DOI: 10.1038/nature10144.
SHENG S, QIAO M, PARDEE A B. Metastasis and AKT activation[J]. J Cell Physiol, 2009, 218(3): 451-454. DOI: 10.1002/jcp.21616.
YU P F, LIU Q, LIU K, et al .Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappa B signaling[J ] . Cytotechnology , 2009, 59(3): 219-229. DOI: 10.1007/s10616-009-9225-9..
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
